Suppressor of cytokine signaling-3 (SOCS3) has multiple functions including inhibition of Janus kinase (Jak) activity, regulation of protein degradation, and suppression of cytokine signaling. SOCS3 modulates macrophage response to cytokines such as IL-6 and leptin that are systemically induced in obesity. Obesity is a suspected risk factor for SOCS3-related pathology such as rheumatoid arthritis and Crohn's disease as well as zoledronic acid (ZA)-induced osteonecrosis of the jaw (ONJ). Thus, understanding the ability of bisphosphonates to modulate SOCS3 is necessary to qualify their contribution to these disorders. ONJ occurs in up to 10% of patients using intravenous bisphosphonates and has an unknown pathogenesis that may be linked to decreased bone turnover, altered vascularity, bacterial invasion, and compromised wound healing. Given the increased risk of ONJ with obesity and importance of macrophages in wound healing, we hypothesized that aminobisphosphonates could contribute to the pathogenesis of ONJ by regulating macrophage responses to cytokines such as leptin and IL-6. We report that ZA is a novel inhibitor of SOCS3 in primary macrophages and human ONJ biopsy specimens. Inhibition of SOCS3 by ZA resulted in significant increases in IL-6 production. SOCS3 transcription is regulated by nuclear accumulation of phosphorylated-Stat3 (P-Stat3). We found that ZA decreased phosphorylation of Stat3 in a mevalonate-pathway dependent manner. However, restoration of P-Stat3 was not sufficient to correct SOCS3 inhibition. We propose that disruption of macrophage SOCS3 expression by amino-bisphosphonates such as ZA may be a novel contributor to inflammatory phenotypes in obesity and the pathogenesis of ONJ.
initial administration [Khan et al., 1997] . The compound is then gradually released during bone remodeling. This generates potential for long-term systemic effects and has been linked to complications such as osteonecrosis of the jaw (ONJ). ONJ is diagnosed when a patient with a history of bisphosphonate use and without previous radiation treatment presents with exposed bone in the oral cavity that fails to heal after 8 weeks [Novince et al., 2009] . A survey of over 700,000 medical claims revealed that those taking IV bisphosphonates were at a four to sixfold increased risk of requiring jaw surgery due to inflammatory changes [Cartsos et al., 2008 ] and a survey of cancer patients specifically taking ZA found a 30-fold increase in risk of ONJ [Wessel et al., 2008] .
In patients taking ZA, obesity is also a risk factor for development of ONJ [Wessel et al., 2008] . Obesity has been linked to significant increases in systemic markers of inflammation such as c-reactive protein and circulating inflammatory cytokines such as leptin, IL-6, and TNF-a [Considine et al., 1996; Das, 2001; Fontana et al., 2007] . Obesity is also a suspected risk factor for SOCS3-related inflammatory disorders such as rheumatoid arthritis and Crohn's disease [Voigt et al., 1994; Mendall et al., 2011] . Given the increasing prevalence of amino-bisphosphonate use, understanding the ability of these compounds to modulate inflammation and macrophage cytokine production is necessary to qualify their contribution to these disorders.
The main function of amino-bisphosphonates such as ZA is to reduce osteoclast activity both by induction of osteoclast apoptosis [Sudhoff et al., 2003 ] and inhibition of osteoclast maturation through blockage of protein prenylation and geranyl-geranylation in myeloid precursor cells [Coxon et al., 2000; Russell et al., 2008] . Although the macrophage and the osteoclast originate from a common precursor, much less is known about the effects of bisphosphonates on macrophage gene expression. Macrophages play an important role in the early phase of wound healing. In addition to the phagocytosis of debris and bacteria, macrophages release cytokines that promote proliferation of fibroblasts and endothelial cells. Some studies have suggested that reduced macrophage infiltration may, in part, be responsible for the increased rate of healing in oral mucosa compared to dermal sites [Szpaderska et al., 2003] . We previously demonstrated that macrophages are present in human ONJ biopsy specimens with a trend toward increased macrophage numbers in patients with IV bisphosphonate-induced ONJ [Scheller et al., 2011] . Thus, understanding the mechanisms by which bisphosphonates regulate macrophage functions, such as cytokine secretion, may provide insight into the pathogenesis of ONJ and lead to discovery of new therapeutic targets. Given the increased risk of ONJ with obesity and the importance of macrophages in wound healing, we hypothesized that amino-bisphosphonates could contribute to the progression of ONJ and other inflammatory disorders by regulating macrophage responses to systemic cytokines such as leptin and IL-6.
MATERIALS AND METHODS

TRANSGENIC MICE
All procedures were approved by the University Committee on the Use and Care of Animals. Mice with the coding sequence for exon17 of the long-form leptin receptor (ObRb) flanked by loxP were obtained from Dr. Martin Myers (University of Michigan) with permission of Dr. Streamson Chua (Columbia University) [McMinn et al., 2004] . Mice with germline transmission of the recombined floxed region and inactivation of leptin receptor signaling were used in our study and are referred to as knock-out (KO) mice. ObRb transgenic s/s (point mutation at tyrosine 1138) and l/l (point mutation at tyrosine 985) mice were the generous gift of Dr. Peter Mancuso (University of Michigan) and are also available from Jackson Labs (Stock No. 008518 and 008385). Genotyping of s/s, l/l, and ObRb KO mice was performed from tail biopsy as described previously [Bates et al., 2003; McMinn et al., 2004; Bjornholm et al., 2007] . Recombination and deletion of the loxP flanked allele was determined using a three-primer system designed by McMinn et al. [2004] . removal, genomic DNA was harvested using the QIAGEN DNeasy kit (Cat:69506) by adding PBS, proteases, and buffer directly to each well followed by incubation of the whole plate at 558C. Harvested DNA was quantified using a UV spectrophotometer at 260 nm. Ratio of 260 nm to 280 nm absorbance was greater than 1.4 for sample acceptance. Ten to 25 ml of supernatant was analyzed with an IL-6 ELISA kit (R&D Systems, Cat:M6000B). Results from each well were normalized to total genomic DNA.
CELL CULTURE
WESTERN BLOT ANALYSIS
Protein was harvested using NP-40 lysis buffer (10% glycerol, 1% NP-40, 50 mM Tris pH 7.4, 200 mM NaCl, 2 mM MgCl 2 , 1 mM PMSF, 1Â Protease Inhibitor Cocktail (Sigma Cat:P8340)). Cells were collected and pelleted in 1 ml ice cold PBS at 48C. Cell pellets were resuspended in 25-50ml of lysis buffer, incubated for 30 min on ice, centrifuged at 13,000 rpm for 10 min, and supernatant harvested. Protein concentration was measured at 595 nm with Bio-Rad protein assay dye concentrate (Cat:500-0006). Protein extracts (30-80mg) were boiled in 2Â SDS sample buffer 5 min and separated on a 12% Tris-HCl polyacrylamide gel (Bio-Rad). Protein was transferred to PVDF membranes using a wet transfer system (Bio-Rad Cat:170-3930). Membranes were blocked in 5% milk (Stat3, P-Stat3, GAPDH; Bio-Rad, Cat:170-6404) or 5% BSA (SOCS3, Sigma, Cat:A7906) 1 h and probed overnight with 1:1,000 P-Stat3 (Cell Signaling:9131) or 1:1,000 SOCS3 (Cell Signaling:2923) and stripped and re-probed the next day with 1:1,000 Stat3 (Cell Signaling:9132) and/or 1:1,000 GAPDH (Chemicon 1 International:MAB374). Signals were amplified with 1:3,000 HRP-conjugated secondary antibody (Santa Cruz Biotechnology) and SuperSignal 1 West Pico Chemiluminescent Substrate (Thermo Scientific, Pierce Product) and developed using film exposure.
HUMAN TISSUE COLLECTION
Biopsies were accessioned with University of Michigan IRB approval. Biopsies were identified as described previously [Scheller et al., 2011] and assigned to one of two groups, no BP history (control) or ONJ. H&E stained slides of all cases were examined to ensure that each specimen contained epithelium and connective tissue. Histological identification of non-vital bone with associated bacterial colonies, consistent with osteonecrosis, was also required.
IMMUNOFLUORESCENCE
Cells were fixed for 5 min in methanol at À208C before PBS wash and permeabilization with 1% Triton-X-100 in PBS. Cells were blocked in PBS þ 2.5% goat serum þ 2.5% donkey serum þ 0.1% Triton-X-100 for 30 min. CD68 primary antibody (1:500, AbCam:ab955) was added in 1:10 diluted block for 1 h and after washing signal was amplified with secondary antibody (1:500 Donkey antimouse Cy TM 3, Jackson ImmunoResearch) for 45 min. Nucleic acids were visualized with DAPI.
IMMUNOHISTOCHEMISTRY Immunohistochemistry was performed as described previously [Scheller et al., 2011] . Formalin-fixed sections were deparaffinized in xylene and rehydrated. Antigen retrieval was performed in pH 6.0 citrate buffer. Endogenous peroxidase was quenched in 3%
hydrogen peroxide for 30 min followed by permeabilization in 0.1% Triton-X-100 in PBS. Slides were blocked with 2.5% normal horse serum. Primary antibodies were added overnight at 48C: CD68 (1:500, Abcam:ab955) and SOCS3 (1:500, Abcam:ab16030 3A) were stimulated with 100 nM leptin and 10 À7 -10 À5 M ZA (Fig. 3B) . The conditioned medium was subsequently analyzed for IL-6 and normalized to total genomic DNA per well. ZA alone induced a 1.68 fold ( P ¼ 0.006) increase of IL-6 in control cells and a 2.44-fold ( P < 0.001) increase in KO cells (Fig. 3B) . Administration of 100 nM leptin induced a leptin-specific 2.01-fold ( P < 0.001) increase of IL-6 in control cells with no change in ObRb KO cells confirming the ability of leptin to induce IL-6 through ObRb (Fig. 3B ). Combination treatment with 10 À5 M ZA and 100 nM leptin produced a synergistic 5.78-fold ( P < 0.001) increase in IL-6 above that induced by ZA or leptin alone (Fig. 3B ). This synergy was not observed in the KO cells (Fig. 3B ).
To determine which signaling pathway was responsible for the increased cytokine production with combined leptin and ZA treatment, we utilized two mouse models with gene targeted deletions in the signaling components of the leptin receptor, ObRb. ObRb has two signaling phosphotyrosines, Tyr1138 and Tyr985, on the cytoplasmic domain of the receptor. Point mutation of Tyr1138, which was generated in s/s gene targeted mice, blocks leptin signaling through P-Stat3, and SOCS3. In contrast, mutation of Tyr985 of the leptin receptor in l/l mice blocks 70-100% of downstream Erk signaling [Myers, 2004] . The signaling deficits of s/s and l/l mice have been previously verified in the central nervous system [Bates et al., 2003; Bjornholm et al., 2007] and in peripheral macrophages [Mancuso et al., 2011] . BMMs harvested from s/s and l/l mice were genotyped (Fig. 3C ) and treated as described above. Repetition of the ELISA experiment revealed a 16.87-fold ( P ¼ 0.001) synergistic increase in IL-6 after combined leptin and 10 À5 M ZA treatment in the s/s BMMs but not in the l/l BMMs (Fig. 3D ). This implies that synergistic induction of IL-6 production by Leptin and ZA requires Tyr985-directed Erk signaling.
ZA BLOCKS SOCS3 PROTEIN ACCUMULATION BY BMMs
The s/s transgenic mice that lack the ability to signal through PStat3 and SOCS3 demonstrated a robust synergistic increase in macrophage IL-6 output. A similar increase was observed after treatment of control macrophages with leptin and 10 À5 M ZA. Since SOCS3 is a known inhibitor of leptin signaling, we hypothesized that ZA may be regulating cellular SOCS3 accumulation. SOCS3 is a negative-feedback regulator of signaling molecules such as leptin and IL-6, and induction of SOCS3 expression can decrease macrophage cytokine production . We found that stimulation of BMMs with 20% FBS for 3 h increased SOCS3 protein 1.8-fold (Fig. 1A) . Treatment with 10 À6 or 10 À5 M ZA inhibited this increase in a dose dependent manner (Fig. 1A) . Leptin induction of SOCS3 protein levels by 2.4-fold at 3 h was also inhibited dose dependently by 10 À6 or 10 À5 M ZA (Fig. 1B) .
Similarly, SOCS3 inhibition after stimulation with 25 ng/ml IL-6 by ZA was noted (Fig. 1C) .
ZA REDUCES PHOSPHORYLATION OF STAT3 IN A MEVALONATE-PATHWAY DEPENDENT MANNER
Since SOCS3 RNA is induced by nuclear accumulation of P-Stat3 and previous reports have suggested that ZA can modulate P-Stat3 levels in clonal macrophages [Reuben et al., 2011] , we investigated the ability of ZA to regulate P-Stat3 in primary BMMs. Addition of 25 ng/ml IL-6 for 0-180 min increased phosphorylation of Stat3 from 5-30 min and again from 120-180 min ( Fig. 2A) . Pretreatment with 10 À5 M ZA for 16-18 h resulted in both an increase in total Stat3 at all time points and a reduction in Stat3 phosphorylation (Fig. 2B) . This approximately 50% reduction in 
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the ratio of P-Stat3 to Stat3, normalized to GAPDH, was statistically significant from 5-15 min (Fig. 2C) . Many of the functions of aminobisphosphonates are mediated by their ability to inhibit the mevalonate pathway. Therefore, mevalonate pathway intermediates GGOH and FOH were added to determine the extent to which specific intermediates may rescue the bisphosphonate-induced P-Stat3 defect. Addition of 10 mM GGOH did not alter phosphorylation of Stat3. In contrast, the addition of 10 mM FOH fully restored levels of P-Stat3 in the presence of 10 À5 M ZA (Fig. 4A ).
CORRECTION OF P-STAT3 SIGNALING IS NOT SUFFICIENT TO RESCUE SOCS3 PROTEIN INHIBITION
P-Stat3 nuclear accumulation induces SOCS3 mRNA transcription [Banks et al., 2000] . Therefore, we sought to determine if cytokine treatment had a similar effect in our system. Addition of 25 ng/ml IL-6 significantly induced SOCS3 mRNA accumulation after 1 h (data not shown). This increase was significantly blunted by treatment with 10 À5 M ZA and rescued by concomitant treatment with 10 mM FOH, but not 10 mM GGOH (Fig. 4B) . Despite the complete rescue of P-Stat3 protein and SOCS3 mRNA levels (Fig. 4A, B) , FOH at 5 mM or 10 mM was not sufficient to rescue SOCS3 protein production (Fig. 5) .
MACROPHAGE-ASSOCIATED SOCS3 LEVELS ARE DECREASED IN HUMAN SPECIMENS
To determine if alterations in SOCS3 were present in human cells and tissue, we analyzed both primary human macrophages and ONJ biopsy specimens. hBMMs were harvested from iliac crest bone marrow of a 60-year old male donor. Harvested cells were strongly positive for CD68, a macrophage marker, when analyzed with immunofluorescence (Fig. 6A) . SOCS3 protein accumulation induced after 5 h of 50 ng/ml IL-6 treatment was inhibited by pre-incubation of the cells with 10 À5 M ZA (Fig. 6B ) similar to studies with mouse BMMs (Fig. 1A-C) . Immunohistochemistry for SOCS3 and CD68 was performed on serial sections of biopsies derived from control human oral ulcerations or ulcerations associated with ONJ. Comparison of SOCS3 staining density in the areas of macrophage infiltration revealed a significant decrease in SOCS3 in the ONJ specimens (16.8 AE 16.2%, P ¼ 001) when compared to controls (70.5 AE 27.1%) (Fig. 6C, D) .
DISCUSSION
SOCS3 is an essential regulator of diverse cellular functions including cytokine production and has been implicated in the pathogenesis of inflammatory pathology such as Crohn's disease and rheumatoid arthritis. We found that the amino-bisphosphonate ZA has the potential to enhance macrophage cytokine secretion by inhibiting SOCS3 protein accumulation. Due to the extended halflife of bisphosphonates and their ability to incorporate into the bone matrix [Kozloff et al., 2010] , it is possible that long-term systemic persistence of these drugs may contribute to inflammatory pathologic processes through the inhibition of SOCS3. Indeed, ONJ, an increasingly recognized complication of aminobisphosphonate treatment, may be linked to altered macrophage SOCS3 activity, as preliminary evidence suggests that SOCS3 protein levels are decreased in ONJ biopsy specimens when compared to controls. However, it is important to recognize a limitation of this study. Except for specimen number 5 that contained a granulomatous reaction (Fig. 6D) , both the controls and the ONJ biopsy specimens represented clinical ulcerations of similar appearance. In all specimens one would expect to see an inflammatory reaction including induction of SOCS3. However, the duration of the ulcers is unknown and their status as acute versus chronic inflammatory lesions may also influence SOCS3 protein levels. Despite this level of information, the approximately fourfold decrease in SOCS3 protein levels in the ONJ specimens suggests that further investigation in this area may provide additional insights on the mechanisms responsible for ONJ. The pathogenesis of ONJ is currently unknown but may be linked to decreased bone turnover, altered vascularity, bacterial invasion, and compromised wound healing [Novince et al., 2009] . Osteoimmunology is an emerging field of research that views regulation of bone metabolism within the context of immune function [Lorenzo et al., 2008] . While the macrophage has long been appreciated as a key component of the immune system, an essential role for macrophages in bone homeostasis was only recently confirmed when induced depletion of macrophages in a mouse model ablated mature osteoblast bone-forming surface [Chang et al., 2008] . In addition to regulation of osteogenesis, macrophage-released cytokines are regulators of fibroblast and endothelial cell proliferation and studies have speculated that reduced macrophage infiltration may, in part, be responsible for increased rates of healing of oral mucosa compared to keratinized dermal sites [Szpaderska et al., 2003] . Thus, dysregulation of critical macrophage functions such as cytokine production may contribute to altered bone remodeling and decreased healing potential observed at sites of ONJ.
We found that ZA at concentrations of 10 À6 -10 À5 M is a novel inhibitor of serum and cytokine-induced SOCS3 in macrophages in vitro. Inhibition of SOCS3 was also observed in human ONJ biopsy specimens in vivo. SOCS3 is a potent regulator of macrophage responses to systemic cytokines such as IL-6 and leptin that are upregulated in states of obesity. Analysis of alendronate release kinetics in rat bone have demonstrated local bisphosphonate concentrations of 10 À3 -10 À4 M at sites of active resorption after 0.4 mg/kg treatment [Sato et al., 1991] . In addition, secreted concentrations of 10 À5 M ZA are readily achieved with ZA-loaded bone cement that has been proposed for local treatment of giant cell tumor and multiple myeloma [Zwolak et al., 2010] . This study reveals that the future use of such devices must consider complications due to inhibition of SOCS3 and enhancement of a destructive inflammatory response. Though our study has focused on SOCS3 inhibition in the context of ONJ, this may also play important roles in other inflammatory conditions such as rheumatoid arthritis [Isomaki et al., 2007] , inflammatory bowel disease [Suzuki et al., 2001] , and Crohn's disease [Lovato et al., 2003 ]. In summary, we conclude that ZA is a novel inhibitor of SOCS3 protein accumulation in macrophages, essentially ''inhibiting the inhibitor'' of signaling by molecules such as leptin and IL-6 (Fig. 7) . Functionally, administration of ZA with leptin promoted a synergistic induction of downstream IL-6 production by primary BMMs that was not present in BMMs lacking the long-form leptin receptor (ObRb). This effect was dependent on ObRb tyrosine 985, likely mediated by the downstream Erk pathway (Fig. 7) . Though ZA was found to decrease both phosphorylation of Stat3 and initial induction of SOCS3 mRNA in a mevalonate-pathway dependent manner, rescue of these defects with FOH was not sufficient to restore SOCS3 protein levels (Figs. 4 and 5) . Thus, the specific mechanism of SOCS3 inhibition is unclear at this point but may involve a post-transcriptional process. Though this study focused on SOCS3 induction by obesity-related cytokines leptin and IL-6, our results suggest wider implications for regulation of additional SOCS3 dependent signaling molecules such as IL-10, LPS and IFN-g. In conclusion, we propose that inhibition of SOCS3 and dysregulation of macrophage cytokine output may contribute to obesityassociated inflammatory disorders and potentially the pathogenesis of ZA-induced ONJ.
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